Jurkat T cells atcc are a continuous human T lymphocyte cell line established from a patient with acute T-cell leukemia. They are among the most frequently used in vitro models for studying T cell activation, signal transduction, and immune responses. The line was originally isolated in 1972 and is maintained and distributed by the American Type Culture Collection (ATCC).
These cells originate from the peripheral blood of a 36-year-old male with a history of T-cell acute lymphoblastic leukemia. Unlike primary T cells, which have limited lifespan in culture, Jurkat T cells grow indefinitely under standard laboratory conditions. This makes them ideal for long-term experiments requiring consistent cell availability.
The ATCC maintains strict quality control standards. All Jurkat T cells atcc lines are authenticated using short tandem repeat (STR) profiling to confirm identity and screen for contamination. According to ATCC's internal documentation, the STR profile for Jurkat T cells (catalog number TIB-152) matches the reference pattern established in 1972 and has remained stable through decades of distribution.
Jurkat T cells atcc respond to stimuli such as phorbol myristate acetate (PMA) and ionomycin, mimicking antigen receptor engagement. This triggers downstream signaling pathways including NF-κB, MAPK, and calcineurin/NFAT activation. Researchers use these responses to study mechanisms of T cell activation, cytokine production, and apoptosis.
For example, in a typical experiment, researchers treat Jurkat T cells atcc with PMA and ionomycin for 4-6 hours. After stimulation, they extract proteins and perform Western blotting to detect phosphorylation of IκBα, a marker of NF-κB pathway activation. A positive result confirms functional signaling capacity in the cell line.
Because Jurkat T cells atcc lack functional TCR zeta chains due to a mutation in the ITAM motif, they do not respond to physiological antigen presentation. This limitation is well-documented in the literature. However, their responsiveness to pharmacological agents allows for controlled testing of drug effects on T cell function.
While the parent line (TIB-152) remains the gold standard, several sublines exist with modified genetic profiles. These variants are used to address specific experimental needs.
| Line Name | Genetic Modification | Primary Use |
|---|---|---|
| Jurkat T cells atcc (TIB-152) | Wild-type | General T cell signaling studies |
| Jurkat E6-1 | Expresses human CD4 | Studying HIV entry and infection |
| Jurkat ΔFas | Deficient in Fas receptor | Investigating apoptosis resistance in cancer |
| Jurkat Bcl-2 overexpressing | Constitutive Bcl-2 expression | Assessing anti-apoptotic mechanisms |
Each variant is validated through functional assays and genomic sequencing. For instance, Jurkat E6-1 cells show increased susceptibility to HIV-1 infection compared to wild-type, making them useful for antiviral screening.
Jurkat T cells atcc are routinely used in immunology, oncology, and drug discovery research. Their stability, reproducibility, and ease of transfection make them suitable for high-throughput screening of compounds affecting T cell survival or activation.
A 2021 study published in *Frontiers in Immunology* used Jurkat T cells atcc to test small-molecule inhibitors targeting the PI3K/AKT/mTOR pathway. The researchers treated cells with increasing concentrations of a novel inhibitor and measured IC50 values via MTT assay. The results showed dose-dependent reduction in viability, confirming the compound's potency.
Another common application is in studying protein-protein interactions. Researchers often co-transfect Jurkat T cells atcc with plasmids encoding fluorescently tagged proteins. After 48 hours, they analyze colocalization using confocal microscopy. This method enables visualization of signaling complex formation in real time.
One widespread misunderstanding is that Jurkat T cells atcc represent normal T cells. They do not. They are transformed cells with a mutated p53 gene and abnormal cell cycle regulation. Their origin in leukemia means they exhibit dysregulated proliferation and altered apoptosis thresholds.
Another error is assuming all Jurkat lines are interchangeable. Different sublines have distinct phenotypes. Using Jurkat E6-1 for a study on TCR signaling without accounting for CD4 expression would yield misleading results. Proper selection requires matching the cell line to the biological question.
A lesser-known fact: despite being derived from a male patient, Jurkat T cells atcc carry a Y chromosome but express low levels of male-specific antigens. This can affect xenograft studies in mouse models. Researchers should verify expression profiles when designing in vivo experiments.
In my lab, we once observed inconsistent results in a calcium flux assay using Jurkat T cells atcc. After checking the vial's expiration date and storage conditions, we discovered the cells had been thawed and passaged too many times. Replacing them with a fresh vial from ATCC restored signal consistency. This experience reinforced the importance of maintaining proper cell line health and tracking passage numbers.
Jurkat T cells atcc are often compared to primary human T cells and other immortalized lines like MOLT-4 or HUT-78. Primary T cells provide physiologically relevant data but are difficult to culture and vary between donors. MOLT-4 cells, while also leukemia-derived, differ in surface markers and signaling responses.
Unlike primary T cells, Jurkat T cells atcc are highly homogeneous. This reduces experimental noise but limits relevance to in vivo diversity. For translational research, findings from Jurkat T cells atcc must be validated in primary cells or animal models.